complement activated igg hexamers assembled cell surface
complement activation antibodies bound pathogens tumors self antigens critical feature natural immune defense number disease processes immunotherapies antibodies activate complement cascade however poorly understood found specific noncovalent interactions fc segments immunoglobulin g igg antibodies resulted formation ordered antibody hexamers antigen binding cells hexamers recruited activated c1 first component complement thereby triggering complement cascade interactions neighboring fc segments manipulated block reconstitute enhance complement activation killing target cells using four human igg subclasses offer general model understanding antibody-mediated complement activation design antibody therapeutics enhanced efficacy
